Clinical trials: NPC, open to volunteers
Nasopharyngeal Cancinoma (NPC)
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
This phase III randomized, double-blind, placebo-controlled trial evaluates whether nanocrystalline megestrol acetate can reduce anorexia in patients with locally advanced nasopharyngeal carcinoma (NPC) undergoing concurrent…
- Trial name
- NCT07796789
- Testing
- Nanocrystalline Megestrol Acetate Oral Suspension
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
This single-center, Phase 1 study is evaluating the safety, tolerability, and preliminary antitumor activity of recombinant human endostatin adenovirus injection (EDS01) given by intratumoral injection in combination with…
- Trial name
- EDS01 HN (NCT07625423)
- Testing
- EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma (NPC), Screening
"Xijiang Project" Screening Cohort for NPC
The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and…
- Trial name
- NCT06787456
- Testing
- EBV antibodies test, EBV DNA test, epidemiological information survey
- Where
- China
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Ming-Yuan Chen
Nasopharyngeal Cancinoma (NPC)
Platinum-Free Regimen in Nasopharyngeal Carcinoma
This study aimed to investigate the efficacy of a platinum-free neoadjuvant regimen (gemcitabine, camrelizumab, endostar, and low-dose radiotherapy) followed by a risk-adapted therapeutic strategy in patients with locally…
- Trial name
- NCT07794488
- Testing
- Endostar (recombinant human endostatin injection)
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Nasopharyngeal Carcinoma (NPC)
Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
To evaluate whether the 2-year local failure-free survival (LRFFS) in Cohort 1 patients with AJCC/UICC 8th edition stage IB-II nasopharyngeal carcinoma who achieved EBV-DNA = 0 after induction chemotherapy and had MRI assessment…
- Trial name
- NCT07789158
- Testing
- reduced dose group, Standard Dose Group, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 269 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
This multicenter, randomized controlled trial is designed to determine whether omitting prophylactic extraction of impacted teeth before radiotherapy leads to an unacceptably higher risk of jaw osteoradionecrosis (JORN) compared…
- Trial name
- NCT07764887
- Testing
- Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction
- Where
- 11 sites in China
- Volunteers
- 536 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma (NPC)
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
This study aims to explore the efficacy and safety of risk-adapted adjuvant therapy based on dynamic EBV-DNA changes and MRI in nasopharyngeal carcinoma patients.
- Trial name
- NCT07762976
- Testing
- Observation, Adjuvant therapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
Re-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life.
- Trial name
- NCT07528183
- Testing
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
This multicenter randomized controlled Phase III trial assesses the efficacy and safety of becotatug vedotin plus anti-PD-1 antibody as maintenance therapy for recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT07705243
- Testing
- Anti-PD1, Anti-PD1 combined with Becotatug Vedotin
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Sun Yat-sen University
Recurrent/ Metastatic NPC
JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma
This study is to determine the activity and tolerability of JS207 as a single agent and in combination cohort with chemotherapy.
- Trial name
- NCT07690787
- Testing
- JS207, Paclitaxel, Capecitabine
- Where
- Hong Kong
- Volunteers
- 49 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Cancinoma (NPC)
Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma
This randomized trial evaluates a multimodal surveillance strategy in nasopharyngeal carcinoma patients with high-risk N3 cervical lymph node involvement after radiotherapy.
- Trial name
- NCT07692906
- Testing
- Multimodal Evaluation-Guided Surveillance Strategy
- Volunteers
- 80 people
- Sponsor
- Xuelei Ma MD